End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.44 CNY | +1.44% |
|
+3.67% | +2.26% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.17 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.26% | 2.39B | - | ||
+2.88% | 93.97B | A- | ||
+6.58% | 41.61B | A- | ||
-13.68% | 33.32B | B- | ||
+77.00% | 28.8B | A | ||
-15.73% | 15.61B | C | ||
-7.87% | 13.27B | B- | ||
-12.55% | 11.46B | D+ | ||
+166.50% | 10.06B | D | ||
-54.80% | 9.09B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300294 Stock
- Ratings China Resources Boya Bio-pharmaceutical Group Co.,Ltd